ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

MARKET SNAPSHOT: U.S. Stocks Rise With Odds Of Intervention

By Kate Gibson, MarketWatch NEW YORK (MarketWatch) -- U.S. stocks rallied Friday to reclaim weekly gains as investors anticipated central-bank moves in Europe as well as by the U.S. Federal Reserve. The market is "bid up on prospects of monetary intervention," said Mark Luschini, chief investment strategist at Janney Montgomery Scott. The Dow Jones Industrial Average (DJI) rose 107.16 points, or 0.8%, to 12,995.09, with Merck & Co. Inc. (MRK) leading gains that included all but two of its 30 components. Merck shares rallied 3.1% after the pharmaceutical company's earnings topped forecasts. The S&P 500 index (SPX) added 14.93 points, or 1.1%, to 1,374.95, with health-care the best performing and energy the sole laggard among its 10 sectors. Amgen Inc. (AMGN) gained 4% after the biotechnology company hiked its 2012 outlook and reported second-quarter profit that exceeded analysts' estimates. The Nasdaq Composite (RIXF) gained 34.52 points, or 1.2%, to 2,927.77. Facebook Inc. (FB) shares slid nearly 13% after the social-networking site offered little reassurance to investors concerned about its lofty valuation. For every stock declining, more than four gained on the New York Stock Exchange, where 261 million shares were exchanged as of 11:40 a.m. Eastern. Global equities gained after German Chancellor Angela Merkel and French President Francois Hollande said they are committed to keeping the euro area together. French newspaper Le Monde reported the European Central Bank was readying to purchase debt. The major stock indexes held gains after a gauge of consumer sentiment came in just above expectations, as did a separate report on U.S. economic growth in the second quarter. . Subscribe to WSJ:

Stock News for Amgen Inc. (AMGN)
10/25/201605:30:00Amgen To Invest In Israel-Based eHealth Ventures
10/24/201616:00:00Amgen Announces Webcast Of 2016 Third Quarter Financial Results
10/20/201616:19:00Amgen Announces Positive Top-Line Results From XGEVA® (Denosumab...
10/14/201616:10:03Current Report Filing (8-k)
10/14/201616:05:00Amgen Announces 2016 Fourth Quarter Dividend
10/14/201616:00:00Amgen Announces Appointment Of Ellen J. Kullman To Board Of Directors
10/10/201609:09:00New Retrospective Analyses Confirm Vectibix® (Panitumumab) Treatment...
10/05/201616:10:00New Amgen Data In Melanoma And Metastatic Colorectal Cancer To...
10/04/201616:00:00Amgen To Participate In Citi Biotech R&D Conference Call
10/03/201616:09:00Study Results Published In Journal of Clinical Oncology Show...
09/29/201609:51:00Amgen, Arrowhead Pharma Agree to Cardiovascular Collaboration
09/29/201607:30:00Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular...
09/28/201616:30:00Amgen Announces Erenumab Significantly Reduces Monthly Migraine...
09/27/201608:32:00Amgen's Myeloma Treatment Study Fails to Meet Primary Endpoint
09/27/201604:00:00Amgen Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib...
09/26/201617:00:00Amgen Opens Nomination Process For LabCentral Residency
09/26/201616:00:00Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License...
09/23/201620:12:00FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23/201619:10:00FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23/201618:56:00FDA Approves Amgen's Biosimilar Version of Humira

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations